53856-93-2

Basic information

• Product Name: Pentanoic acid, 5-bromo-4-oxo-, methyl ester
• CAS NO: 53856-93-2
• Molecular Formula: C6H9BrO3
• Molecular Weight: 209.04
• Mol File: 53856-93-2.mol
• Article Data: 32

Chemical Properties

• CAS DataBase Reference: Pentanoic acid, 5-bromo-4-oxo-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Pentanoic acid, 5-bromo-4-oxo-, methyl ester(53856-93-2)
• EPA Substance Registry System: Pentanoic acid, 5-bromo-4-oxo-, methyl ester(53856-93-2)

Safety Data

• Hazardous Substances Data: 53856-93-2(Hazardous Substances Data)

Upstream product

• 624-45-3 levulinic acid methyl ester 
• 67-56-1 methanol 
• 539-88-8 4-oxopentanoic acid ethyl ester 
• 123-76-2 levulinic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 1490-25-1 succinic acid monomethylester chloride 
• 3878-55-5 methyl hydrogen succinate 
• 52944-79-3 3,3'-Dimethoxycarbonylpropanoic anhydride 
• 109988-02-5 2-methoxycarbonylethyl (trimethylsilyl)methyl ketone 
• 7770-06-1 methyl 5-diazo-4-oxopentanoate 
• 186581-53-3 diazomethane 
• 61882-39-1 4-methoxy-butyryl chloride 

Downstream Products

• 84028-78-4 (5-methoxy-2,5-dioxopentyl)triphenylphosphonium bromide 
• 5451-09-2 5-aminolevulinic acid hydrochloride 
• 134334-40-0 2-Benzylhexahydro-2H-pyrido<1,2-a>pyrazin-7(6H)-one 
• 134334-50-2 Hexahydro-2-(2-methoxyphenyl)-2H-pyrido<1,2-a>pyrazin-7(6H)-one 
• 141856-04-4 2-Benzylhexahydropyrrolo<1,2-a>pyrazin-6(2H)-one 
• 141856-10-2 2-Benzylhexahydro-8a-hydroxypyrrolo<1,2-a>pyrazin-6(2H)-one 
• 141856-09-9 2-Benzylhexahydro-8a-methoxypyrrolo<1,2-a>pyrazin-6(2H)-one 
• 141856-08-8 Methyl 5-Benzylpiperazin-2-ylpropionate 
• 141856-22-6 Hexahydro-2-(2-methoxyphenyl)pyrrolo<1,2-a>pyrazin-6(2H)-one 
• 141856-18-0 2-Benzyl-7-oxo-octahydro-pyrido[1,2-a]pyrazine-6-carboxylic acid methyl ester 
• 141856-19-1 Methyl 2-Benzyloctahydro-7-oxo-2H-pyrido<1,2-a>pyrazine-8-carboxylate 
• 141856-26-0 Methyl 4-(2-Methoxyphenyl)piperazin-2-ylpropionate 
• 141856-17-9 Methyl 4-Benzyl-2-methoxycarbonylethylpiperazin-1-ylacetate 
• 141856-03-3 2-(2-Methoxy-phenyl)-7-oxo-octahydro-pyrido[1,2-a]pyrazine-6-carboxylic acid methyl ester 

Relevant articles and documents

Radiochemical Synthesis and Evaluation of 13N-Labeled 5-Aminolevulinic Acid for PET Imaging of Gliomas

The endogenous amino acid, 5-aminolevulinic acid (5-ALA), has received significant attention as an imaging agent, including ongoing clinical trials for image-guided tumor resection due to its selective uptake and subsequent accumulation of the fluorescent protoporphyrin IX in tumor cells. Based on the widely reported selectivity of 5-ALA, a new positron emission tomography imaging probe was developed by reacting methyl 5-bromolevulinate with [13N] ammonia. The radiotracer, [13N] 5-ALA, was produced in high radiochemical yield (65%) in 10 min and could be purified using only solid phase cartridges. In vivo testing in rats bearing intracranial 9L glioblastoma showed peak tumor uptake occurred within 10 min of radiotracer administration. Immunohistochemical staining and fluorescent imaging was used to confirm the tumor location and accumulation of the tracer seen from the PET images. The quick synthesis and rapid tumor specific uptake of [13N] 5-ALA makes it a potential novel clinical applicable radiotracer for detecting and monitoring tumors noninvasively.

Synthesis and characterization of altaicadispirolactone

Altaicadispirolactone was synthesized via a simple route. In this route, levulinic acid was used as a starting material, and bromination followed by hydrolysis and BF3·OEt2-catalyzed cyclization were carried out. A single-crystal ORTEP drawing has been created and more detailed crystallographic data of the compound has been obtained from X-ray analysis. Copyright Taylor & Francis, Inc.

Preparation method 5 - ALA intermediate 5 - bromoolevulinic acid ester

The invention relates to a preparation method of 5 - ALA intermediate 5 - bromoacetyl ester, which is characterized by comprising the following steps: (S1) reaction of the urotropine and a bromine source to prepare the urotropine bromine complex. (S2) Lourotropine bromide complex and levulinic acid ester reaction. Gave 5 - bromoolevulinic acid ester. Compared with the prior art, a bromo reagent such as liquid bromine and 5 - is used directly, NBS-site bromination product yield is increased 5 - 10% or more. The defect that 3 -position bromination or multi-site bromination product is large and separation is difficult in the bromination reaction is overcome. The method is cheap and easily available in raw materials, simple and convenient to operate and suitable for large-scale preparation 5 - ALA intermediate 5 - bromolevulinic acid ester .

DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES

The application describes dihydropyrimidine derivatives which are useful in the treatment or prevention of HBV infection or of HBV-induced diseases, more particularly of HBV chronic infection or of diseases induced by HBV chronic infection, as well as pharmaceutical or medical applications thereof.

Structure-activity relationship study of thiazolyl-hydroxamate derivatives as selective histone deacetylase 6 inhibitors

Several human diseases are associated with aberrant epigenetic pathways mediated by histone deacetylases (HDACs), especially HDAC6, a class IIb HDACs, which has emerged as an attractive target for neurodegenerative and autoimmune disease therapeutics. In a previous study, we developed the novel HDAC6-selective inhibitor 9a ((E)-N-hydroxy-4-(2-styrylthiazol-4-yl)butanamide) and showed that it has anti-sepsis activity in vivo. In this study, we conducted structure-activity relationship (SAR) studies to optimize the activity and selectivity of HDAC6, synthesizing its derivatives with various aliphatic linker sizes and cap structures. We identified 6u ((E)-N-hydroxy-3-(2-(4-fluorostyryl)thiazol-4-yl)propanamide), which has nanomolar inhibition activity and a 126-fold selectivity for HDAC6 over HDAC1. Through the docking analyses of 6u against HDAC subtypes, we revealed the importance of the optimal aliphatic linker size, as well as the electronic substituent effect and rigidity of the aryl cap group. Thus, we suggest a new rationale for the design of HDAC6-selective inhibitors.